When Is the Emergency Actually Over? Vascular Occlusion Recovery and the Re-Injection Window

Every course covers the first sixty minutes. Recognize, stop, flood the territory, escalate. That material exists in abundance and it is the part injectors rehearse.

Almost nobody covers week two.

Vascular occlusion recovery is not an event, it is a course of treatment, and the emergency is not over when the color comes back in the chair. It may be weeks from then. The clinician who treats return of perfusion as the end of the episode, sends the patient home with instructions to call if anything changes, and books them back in ten days for a touch-up has correctly managed the first hour and mismanaged everything after it.

This piece is about everything after it: the endpoints, the daily recheck, what to do with a case that has not resolved, when the skin breaks, when to involve hyperbaric oxygen, and the window in which that territory does not get injected again.

Endpoint one: perfusion returns — the end of the session, not the episode

The first endpoint is the one that answers the question injectors ask most often during an event: when do I stop injecting hyaluronidase?

You stop when perfusion returns. The moment tissue returns to normal and to its baseline — color matching, capillary refill comparable to the surrounding and contralateral skin, temperature matched, pain settling — is the moment you know the intervention has done what it needed to do. Note what the endpoint is not: it is not an arbitrary volume of enzyme, and it is not the amount that felt like enough. It is a perfusion finding. Our discussion of dissolving filler covers the enzyme itself.

Then you keep watching. The patient may be in the office for a couple of hours after that point, and they should be. Hyaluronidase has a limited duration of action, product may remain, and inflammation and edema continue to accumulate for hours after the initial event — so perfusion that has improved can deteriorate again while the patient is still with you. Photographs at fixed intervals are how you detect that, because gradual re-deterioration is precisely the change a human eye adapts to and fails to notice.

Reaching this endpoint means the session can end. It does not mean the episode has.

These figures reflect Michelle Langston's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.

Endpoint two: the daily recheck until complete resolution

The patient comes back the next day. And the day after. Daily, until this is completely resolved.

That is the part most protocols omit and it is where unresolved cases are actually caught. A patient who was perfusing well on leaving can have re-deteriorated overnight, and nobody was looking.

Each recheck is the same five-step perfusion assessment you ran on the day: scan the whole territory rather than the injection point, ask about the pain trajectory, compare capillary refill against the matched contralateral site, compare temperature, and follow the vascular trajectory. Plus a photograph in the standardized series, and a direct question about vision if the treated region was anywhere in the midface, nose, glabella or periorbital area.

Resolved means all of the following:

• Color matches the contralateral side and the pre-treatment baseline photograph
• Capillary refill is equal to surrounding and contralateral skin
• Temperature is equal to the matched contralateral site
• Pain has resolved rather than plateaued
• No new lesions — no blistering, no pustules, no crusting
• The photographic series demonstrates return to baseline

"The patient feels better" is not on that list. Symptomatic improvement is welcome and it is not an endpoint, particularly in a field where anesthesia or analgesia is in play.

What can still go wrong in week one

Three things happen in the first week that change management.

Deterioration after apparent recovery. Edema builds over the first day or two, and a compressive contribution can worsen as it does. A patient who looked fully recovered at hour three and looks worse at hour thirty has not relapsed mysteriously; the tissue pressure has changed. Treat it as an active problem.

Persistence. Pain that has not settled, a rash that has not resolved, a territory that still looks dusky at day two or three. This is the presentation that gets rationalized — the clinician has already treated it, and there is a strong pull toward believing the treatment worked. Persistence means it did not, or not completely.

Skin breakdown. Blistering and pustules mean the tissue underneath has continued to be ischemic. That is the finding you are trying to prevent by catching everything above it, and when it appears it is an escalation, not a stage to be observed.

Retreating an unresolved case

If a patient presents at day three still in pain, still with a rash and now with pustules, the question of whether to re-treat has a clear answer: yes.

The reasoning is straightforward. Those findings mean product is still obstructing perfusion, or compression is still present, or both. Hyaluronidase is an enzyme with a limited duration of action, and a single session may not manage the entire complication — it is a tool, not a guarantee, and one administration is not a course of treatment. Persistent findings after an initial administration are an indication to give more, directed the same way: to the territory and to where the needle tip was, not to the entry point.

What to reassess before re-treating:

• The territory. Has it extended? The scan may need to widen.
• The original record. Product, volume per pass, plane, entry and vector. That record is what defines the tissue you need to saturate.
• The differential. Perfusion findings — cool skin, delayed refill, dusky color in a vascular distribution — pull toward ongoing ischemia. Their absence, in a patient with a persistent inflammatory picture, raises other possibilities and is a reason to involve a colleague rather than to keep dosing.
• Whether you should still be managing this alone. A case that has not resolved after appropriate treatment is a case that warrants another set of eyes, and the threshold for involving your medical director, a dermatologist or a plastic surgeon should be low. You are not alone in this — the community takes care of each other when these are managed well, and a solo practitioner in particular should have that relationship established before it is needed.

When the skin has broken, a second set of considerations applies. The area is now a wound and needs wound care. Decisions about antimicrobial cover, other pharmacological adjuncts and specialist referral are individual clinical judgments made with your medical director and the treating specialists — they are outside the scope of this article and should not be protocolized from a web page.

Hyperbaric oxygen: build the pathway before you need it

Hyperbaric oxygen therapy may be considered for a case with significant, non-resolving ischemia and threatened tissue. The point worth making is not clinical but logistical.

Hyperbaric referral is part of your emergency protocol, and it needs to exist before there is an emergency. That means knowing, on an ordinary day: where the nearest chamber is, what its hours are, whether it accepts urgent referrals, what its referral mechanism is, and who to telephone. A clinician searching for a hyperbaric facility while a patient's nasal ala is dusky is a clinician who has lost the hours that mattered.

Be honest about the evidence. The literature on hyperbaric oxygen in filler-related ischemia is case reports and small series, not controlled trials, and it is an adjunct to reversal and perfusion management rather than a substitute. That is a reason to establish the pathway and use judgment, not a reason to dismiss it. It sits in the protocol alongside the other things you arrange in advance: which emergency department, whether it has interventional radiology, which colleague you call, and where the hyaluronidase is stored.

The equivalent advance planning for visual symptoms is even more time-critical. Any visual change is an immediate escalation with no watch-and-wait — the patient goes to an emergency department, preferably one with interventional radiology, accompanied, with direct clinician-to-clinician handover of exactly what was injected. Our piece on whether injectables can cause blindness covers the mechanism.

The re-injection window

Here is the rule that gets broken most often, usually with good intentions.

Do not re-inject that territory for at least two to three weeks, and not until the patient has had full tissue recovery. Both conditions, not either.

Four reasons stand behind it.

The tissue is still remodeling. An area that has been ischemic, treated with an enzyme and inflamed is not in a steady state at day ten, regardless of how it looks from the outside.

Hyaluronidase does not respect the product boundary. The enzyme degrades native hyaluronic acid as well as injected filler. The treated field has lost endogenous substrate, and the local environment and its response to new product are not what they were.

Assessment is compromised. Residual erythema, residual pigment change and residual induration all degrade the baseline against which you would have to judge a new treatment. Inject into that and you have lost the ability to recognize a second event — which is precisely the situation you least want to be in, in a territory that has already demonstrated it can be occluded.

The patient has demonstrated risk in that location. Something about that anatomy, that plane or that approach produced an occlusion once. Repeating it before you have reconsidered the approach is not a plan.

Pressure to compress this window is real and it is usually social. The result is asymmetric, the patient is distressed, and there is an event coming. Hold the window anyway, and manage the situation with the conversation rather than the syringe. Explaining at the outset that recovery is measured in weeks makes the later conversation dramatically easier, which is one more reason to describe the expected course honestly rather than optimistically — the same principle that governs setting expectations for ordinary treatments, including the common reactions patients ask about.

When you do re-treat, treat it as a new case. New photographic baseline. Reconsidered approach — instrument, plane, volume per pass, whether that region should be treated that way at all in this patient. And a documented discussion of the previous event.

The long tail: pigment and texture

Two findings can persist well past the point where perfusion is normal and should be anticipated rather than discovered.

Post-inflammatory hyperpigmentation is common after a significant inflammatory or ischemic insult, particularly in richly pigmented skin, and it can take months to fade. Sun protection matters during that period. And any area that blistered or broke down can leave textural change or scarring, which is a matter for wound care and, where indicated, specialist management.

Neither changes the perfusion assessment, but both change the patient conversation, and both are reasons to keep the photographic series going past the point where the emergency is over.

The team debrief

One more thing belongs in week one or two: a debrief with the team. What did we recognize, when, and what delayed us? Was the hyaluronidase where it should have been? Did everyone know their role? What changes before the next patient?

Preparedness is built on quiet days. A complication that has been managed and then examined makes the office measurably safer; one that is managed and never discussed teaches nobody anything. That is the same logic as a case review after a code, and it is one of the more directly transferable habits from emergency practice.

If you are building this kind of system alongside your injectable technique, Empire's Complete Dermal Filler Training, Complete Facial Aesthetic Training and Anatomical Based Aesthetics Training teach injection under hands-on supervision, which is where the judgment underneath the protocol is formed.

Related guides in this cluster

Part of Vascular Occlusion: Recognition and Response.

Clinical GuideThe Expected Filler Injection Response — Building the Baseline That Lets You Recognize IschemiaThe expected filler injection response — erythema, edema, ecchymosis — and how a trained normal baseline makes early ischemia recogniza Clinical GuideThe Golden Triangle — Why the Filler Deposit Site Isn't Where You Put the Needle InThe filler deposit site sits at the needle tip, not the entry point — about half an inch away, further with a cannula. Why that gap dec Clinical GuideImmediate, Early and Late — The Three Windows of Vascular Occlusion OnsetVascular occlusion onset is not one moment. Organize the picture into immediate, early and late windows — detection runs days past the